Q-omics provides the consensus-scored SPRR2E profile across patient tissues and cancer cell-line models. SPRR2E expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SPRR2E is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, SPRR2E RNA expression shows 8,820 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BLCA, LUSC, and ESCA as cancer lineages where SPRR2E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRR2E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRR2E survival associations across molecular data types. SPRR2E RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRR2E RNA expression–survival associations across cancer types. High SPRR2E expression shows unfavorable associations in BLCA, COAD, PAAD, BRCA and SKCM, but favorable associations in LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for SPRR2E RNA expression.
This table summarizes SPRR2E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPRR2E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRR2E shows lower tumor expression in BRCA and KIRP and higher tumor expression in LUSC, COAD and STAD. The LUSC box plot shows higher SPRR2E RNA expression in tumor versus normal tissue (log2 FC = +4.824, t-test p < 0.001).
This table shows molecular features associated with SPRR2E in patient tissues and cancer cell lines. In patient samples, SPRR2E shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRR2E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
